RFL vs CASI vs IMVT vs HALO

For growth investors, Rafael Holdings, Inc.

(RFL) is the stronger pick with 44. 0% revenue growth year-over-year, versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 5x trailing P/E (8. 1x forward), making it the more compelling value choice. Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: HALO returned +570. 7% versus CASI's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.

(CASI) is the lower-risk stock at -0. 12β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately -1220% more volatile than CASI relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Rafael Holdings, Inc.

(RFL) is pulling ahead at 44. 0% versus -15. 8% for CASI Pharmaceuticals, Inc. (CASI). On earnings-per-share growth, the picture is similar: Rafael Holdings, Inc. grew EPS 28. 3% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, RFL leads at 30. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -33. 3% for Rafael Holdings, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -28. 5% for RFL. At the gross margin level — before operating expenses — HALO leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for IMVT: 67.

2% to $45. 50.

In this comparison, CASI (31.

1% yield) pays a dividend. RFL, IMVT, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CASI Pharmaceuticals, Inc.

(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 12), 31. 1% yield). Both have compounded well over 10 years (CASI: -99. 0%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RFL (Real Estate) and CASI (Healthcare) and IMVT (Healthcare) and HALO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RFL is a small-cap high-growth stock; CASI is a small-cap income-oriented stock; IMVT is a small-cap quality compounder stock; HALO is a small-cap high-growth stock. CASI pays a dividend while RFL, IMVT, HALO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.